

AMENDMENT TO THE SPECIFICATION

Please amend the specification as shown below, without prejudice or disclaimer.

Please insert the new sequence listing immediately following paragraph [0104]. A paper copy of the new sequence listing is attached.

Please replace paragraph [0045] with the following amended paragraph:

[0045] Interferons may also be suitable cytokines for use in practicing the present invention. There are three main classes of interferon (alpha interferon (IFN- α), beta interferon (IFN- β) and gamma interferon (IFN- γ)) and at least 22 subtypes from among these. Many of these are available commercially. For instance, IFNs are commercially available as INFERGEN® (interferon alfacon-1; Intermune), Viraferon® (Schering-Plough), Roferon-A® (Roche) Wellferon® (Glaxo SmithKline), IFN α 2b (Schering Canada, Pointe-Claire, Quebec), IFN beta-1b (Betaseron®; Berlex Laboratories), Avonex® (IFN beta-1a; Biogen); and Rebif®(IFN beta-1a; Serono, Pfizer), Actimmune® Interferon gamma-1b; Intermune). Preparations containing multiple IFN species in a single preparation are also available (i.e., IFN-alpha N3 or Alferon N). Variant and modified IFNs are also well-known (i.e., Maral, et al. Proc Am Soc Clin Oncol 22: page 174, 2003 (abstr 698); pegylated interferon alpha/Pegasys® (Roche); Peg Intron® (Schering Plough)). In one embodiment, IFN α 2b is administered at at least 10 MU/m²/day (IV) at least two, three, four or five times per week for at least two weeks. In another embodiment, IFN α 2b is administered at at least 20 MU/m²/day (IV) at least five times per week for at least four weeks. Other cytokines may also be suitable for practicing the present invention, as is known in the art.